MacroGenics

Yahoo Finance • 11 days ago

What's going on in today's after hours session

The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT SPRC [https://www.chartmill.co... Full story

Yahoo Finance • 25 days ago

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ P... Full story

Yahoo Finance • last month

Thursday's after hours session: top gainers and losers

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] GAINERS TICKER CHANGE COMMENT MODV [https://www.chartmill.com/stock/quote/MODV/... Full story

Yahoo Finance • last month

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents... Full story

Yahoo Finance • last month

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective a... Full story

Yahoo Finance • 2 months ago

STNG Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of Scorpio Tankers Inc (Symbol: STNG) crossed above their 200 day moving average of $45.95, changing hands as high as $47.89 per share. Scorpio Tankers Inc shares are currently trading up about 2.7% on the... Full story

Yahoo Finance • 3 months ago

MacroGenics' SWOT analysis: biotech firm's stock faces pivotal year ahead

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics, finds itself at a critical juncture as it navigates through a challenging biotech landscape. Acc... Full story

Yahoo Finance • 4 months ago

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment... Full story

Yahoo Finance • 5 months ago

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC,... Full story

Yahoo Finance • 5 months ago

MacroGenics Announces Date of First Quarter 2025 Financial Results

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of... Full story

Yahoo Finance • 6 months ago

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase... Full story

Yahoo Finance • 7 months ago

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment... Full story

Yahoo Finance • 7 months ago

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment o... Full story

Yahoo Finance • 8 months ago

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and state laws by certain officers of the companies of MacroGenics, Inc. (NASDAQ: MGNX), Apellis P... Full story

Yahoo Finance • last year

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? (CORRECTED)

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? (CORRECTED) Editor’s note: This story has been updated to correct an error in the price a... Full story

Yahoo Finance • 2 years ago

Shareholders in MacroGenics (NASDAQ:MGNX) are in the red if they invested three years ago

It is a pleasure to report that the MacroGenics, Inc. (NASDAQ:MGNX) is up 74% in the last quarter. But that doesn't change the fact that the returns over the last three years have been disappointing. In that time, the share price dropped 6... Full story

Yahoo Finance • 2 years ago

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results

Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET... Full story

Yahoo Finance • 2 years ago

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer,... Full story

Yahoo Finance • 2 years ago

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipeline Multiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC)Cash runway through 2025 with $270 million in non-dilutive fu... Full story

Yahoo Finance • 2 years ago

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today... Full story